Migraines can be unpredictable and debilitating and effect so many people, with few options for treatment and prevention available at present - this could be a great breakthrough for sufferers!
A new approach to preventing migraines can cut the number and severity of attacks, clinical trials show. About 50% of people on one study halved the number of migraines they had each month, which researchers at King's College Hospital called a "huge deal". The treatment is the first specifically designed for preventing migraine and uses antibodies to alter the activity of chemicals in the brain. Research has shown a chemical in the brain - calcitonin gene-related peptide or CGRP - is involved in both pain and sensitivity to sound and light in migraine. Drug companies are racing to develop antibodies that neutralise CGRP. Some work by sticking to CGRP, while others block the part of a brain cell with which it interacts. One study found 50% of those given the antibody injections halved their number of migraine days per month.